Free Trial

Sanctuary Advisors LLC Makes New Investment in Cabot Co. (NYSE:CBT)

Cabot logo with Basic Materials background

Sanctuary Advisors LLC bought a new stake in shares of Cabot Co. (NYSE:CBT - Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 9,912 shares of the specialty chemicals company's stock, valued at approximately $928,000.

Several other hedge funds have also bought and sold shares of the stock. Assenagon Asset Management S.A. raised its stake in shares of Cabot by 571.9% during the second quarter. Assenagon Asset Management S.A. now owns 127,116 shares of the specialty chemicals company's stock worth $11,681,000 after acquiring an additional 108,197 shares in the last quarter. Capital Research Global Investors increased its stake in shares of Cabot by 22.9% in the first quarter. Capital Research Global Investors now owns 521,486 shares of the specialty chemicals company's stock worth $48,081,000 after buying an additional 97,101 shares during the period. Earnest Partners LLC increased its stake in shares of Cabot by 2.4% in the second quarter. Earnest Partners LLC now owns 3,363,398 shares of the specialty chemicals company's stock worth $309,063,000 after buying an additional 80,096 shares during the period. American Century Companies Inc. increased its stake in shares of Cabot by 7.3% in the second quarter. American Century Companies Inc. now owns 976,709 shares of the specialty chemicals company's stock worth $89,750,000 after buying an additional 66,171 shares during the period. Finally, Sei Investments Co. increased its stake in shares of Cabot by 5.9% in the second quarter. Sei Investments Co. now owns 913,259 shares of the specialty chemicals company's stock worth $83,919,000 after buying an additional 51,178 shares during the period. 93.18% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CFO Erica Mclaughlin sold 23,274 shares of the company's stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $99.79, for a total value of $2,322,512.46. Following the transaction, the chief financial officer now owns 59,814 shares in the company, valued at $5,968,839.06. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Cabot news, CFO Erica Mclaughlin sold 23,274 shares of the business's stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $99.79, for a total value of $2,322,512.46. Following the completion of the transaction, the chief financial officer now owns 59,814 shares of the company's stock, valued at approximately $5,968,839.06. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Sean D. Keohane sold 25,617 shares of the business's stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $101.55, for a total value of $2,601,406.35. Following the completion of the transaction, the chief executive officer now directly owns 331,174 shares of the company's stock, valued at approximately $33,630,719.70. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 71,939 shares of company stock worth $7,308,812 in the last quarter. Corporate insiders own 3.07% of the company's stock.

Wall Street Analysts Forecast Growth

CBT has been the topic of several analyst reports. StockNews.com downgraded shares of Cabot from a "strong-buy" rating to a "buy" rating in a research note on Monday, June 24th. JPMorgan Chase & Co. lifted their target price on shares of Cabot from $95.00 to $105.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 7th. Finally, UBS Group decreased their target price on shares of Cabot from $103.00 to $98.00 and set a "neutral" rating on the stock in a research note on Tuesday, August 6th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $101.75.

Read Our Latest Stock Analysis on CBT

Cabot Stock Up 1.5 %

Shares of CBT stock traded up $1.64 during mid-day trading on Friday, reaching $112.41. 153,783 shares of the company's stock traded hands, compared to its average volume of 335,941. Cabot Co. has a 12 month low of $65.10 and a 12 month high of $113.12. The company has a market cap of $6.16 billion, a P/E ratio of 13.37, a P/E/G ratio of 0.93 and a beta of 1.19. The company has a quick ratio of 1.45, a current ratio of 2.22 and a debt-to-equity ratio of 0.72. The company's 50-day moving average price is $104.12 and its 200-day moving average price is $98.99.

Cabot (NYSE:CBT - Get Free Report) last announced its earnings results on Monday, August 5th. The specialty chemicals company reported $1.92 EPS for the quarter, beating analysts' consensus estimates of $1.72 by $0.20. Cabot had a net margin of 12.05% and a return on equity of 26.99%. The firm had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $1 billion. During the same quarter in the previous year, the business posted $1.42 EPS. The company's quarterly revenue was up 5.0% on a year-over-year basis. On average, equities analysts expect that Cabot Co. will post 7.07 earnings per share for the current fiscal year.

About Cabot

(Free Report)

Cabot Corporation operates as a specialty chemicals and performance materials company. The company operates through two segments, Reinforcement Materials and Performance Chemicals. It offers reinforcing carbons that are used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites solutions.

Featured Stories

Institutional Ownership by Quarter for Cabot (NYSE:CBT)

→ 625,000% Gain (From Crypto Swap Profits) (Ad)

Should you invest $1,000 in Cabot right now?

Before you consider Cabot, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cabot wasn't on the list.

While Cabot currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in 2025 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Strong Markets Meet Rising Volatility—Are Your Investments Safe?
Analysts Bullish on AI-Powered Healthcare: Intuitive Surgical’s 30% Upside
Oracle’s Cloud Shift Pays Off: Will Momentum Continue?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines